Research progress on risk factors for retinopathy of prematurity_Chinese Journal of Ocular Fundus Diseases

Authors：

Liu Jianhua , Zhang Chao , Yin Huaiqing ,  Li Hong

Department of Neonatal Intensive Care, First Hospital of Shanxi Medical University, First Clinical Medical College, Taiyuan 030001, China;

Corresponding?author：

Li Hong, Email: lihong7374@163.com

Keywords：

Premature infant; Retinopathy; Risk factors; Prevention and Therapy; Review

DOI：

10.3760/cma.j.cn511434-20250901-00377

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Retinopathy of prematurity (ROP) is a serious ophthalmic disease threatening the vision of premature infants, characterized by abnormal retinal vascular development and pathological neovascularization. Its pathogenesis follows a two-stage model of “early hyperoxia inhibiting angiogenesis - late hypoxia promoting neovascularization,” in which oxidative stress damage, inflammatory immune activation, and abnormal expression of growth factors such as vascular endothelial growth factor and insulin-like growth factor-1 play key roles. Current studies indicate that the occurrence of ROP is closely associated with maternal factors (such as gestational hypertension, diabetes, smoking during pregnancy) and fetal factors (including low birth weight, low gestational age, inappropriate oxygen therapy, anemia, blood transfusion, multiple pregnancies, nutritional imbalances, infections, and genetic susceptibility), among which low birth weight and low gestational age are independent risk factors, while the clinical management of oxygen therapy parameters (duration, concentration, and fluctuations) is particularly important. Given the rapid progression, high blindness rate, and poor prognosis of ROP, there is an urgent need to achieve early precise identification and intervention through multifactorial integration models. Future research should further explore the interaction mechanisms of risk factors and develop individualized prevention and treatment strategies to improve the long-term quality of life for affected children.

1.	Crouch ER, Kraker RT, Wallace DK, et al. Secondary 12-month ocular outcomes of a phase 1 dosing study of Bevacizumab for retinopathy of prematurity[J]. JAMA Ophthalmol, 2020, 138(1): 14-20. DOI: 10.1001/jamaophthalmol.2019.4488.
2.	Zhang RH, Liu YM, Dong L, et al. Prevalence, years lived with disability, and time trends for 16 causes of blindness and vision impairment: findings highlight retinopathy of prematurity[J/OL]. Front Pediatr, 2022, 10: 735335[2022-03-11]. https://pubmed.ncbi.nlm.nih.gov/35359888/. DOI: 10.3389/fped.2022.735335.
3.	Gyllensten H, Humayun J, Sj?bom U, et al. Costs associated with retinopathy of prematurity: a systematic review and meta-analysis[J/OL]. BMJ Open, 2022, 12(11): e057864[2022-11-24]. https://pubmed.ncbi.nlm.nih.gov/36424118/. DOI: 10.1136/bmjopen-2021-057864.
4.	Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity[J]. Ophthalmology, 2015, 122(1): 200-210. DOI: 10.1016/j.ophtha.2014.07.050.
5.	Zhang SM, Fan B, Li YL, et al. Oxidative stress-involved mitophagy of retinal pigment epithelium and retinal degenerative diseases[J]. Cell Mol Neurobiol, 2023, 43(7): 3265-3276. DOI: 10.1007/s10571-023-01383-z.
6.	de Almeida VO, Pereira RA, Amantéa SL, et al. Neonatal diseases and oxidative stress in premature infants: an integrative review[J]. J Pediatr (Rio J), 2022, 98(5): 455-462. DOI: 10.1016/j.jped.2021.11.008.
7.	Romero-Maldonado S, Montoya-Estrada A, Reyes-Mu?oz E, et al. Efficacy of water-based vitamin E solution versus placebo in the prevention of retinopathy of prematurity in very low birth weight infants: a randomized clinical trial[J/OL]. Medicine (Baltimore), 2021, 100(31): e26765[2021-08-06]. https://pubmed.ncbi.nlm.nih.gov/34397821/. DOI: 10.1097/MD.0000000000026765.
8.	Fevereiro-Martins M, Guimar?es H, Marques-Neves C, et al. Retinopathy of prematurity: contribution of inflammatory and genetic factors[J]. Mol Cell Biochem, 2022, 477(6): 1739-1763. DOI: 10.1007/s11010-022-04394-4.
9.	Wiszniak S, Schwarz Q. Exploring the intracrine functions of VEGF-A[J/OL]. Biomolecules, 2021, 11(1): 128[2021-01-19]. https://pubmed.ncbi.nlm.nih.gov/33478167/. DOI: 10.3390/biom11010128.
10.	Fu Y, Lei C, Qibo R, et al. Insulin-like growth factor-1 and retinopathy of prematurity: a systemic review and meta-analysis[J]. Surv Ophthalmol, 2023, 68(6): 1153-1165. DOI: 10.1016/j.survophthal.2023.06.010.
11.	Furuncuoglu U, Vural A, Kural A, et al. Serum vascular endothelial growth factor, insulin-like growth factor-1 and Aflibercept levels in retinopathy of prematurity[J]. Jpn J Ophthalmol, 2022, 66(2): 151-158. DOI: 10.1007/s10384-021-00895-9.
12.	中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專委會. 中國早產兒視網膜病變分類和治療專家共識(2023年)[J]. 中華眼底病雜志, 2023, 39(9): 720-727. DOI: 10.3760/cma.j.cn511434-20230815-00346.Retinal Disease Group of Ophthalmology Branch, Chinese Medical Association, Fundus Disease Specialized Committee of Ophthalmology Branch, Chinese Medical Doctor Association. Expert consensus on the classification and treatment of retinopathy of prematurity in China (2023 edition)[J]. Chin J Ocul Fundus Dis, 2023, 39(9): 720-727. DOI: 10.3760/cma.j.cn511434-20230815-00346.
13.	Hunter A, Aitkenhead M, Caldwell C, et al. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy[J]. Hypertension, 2000, 36(6): 965-969. DOI: 10.1161/01.hyp.36.6.965.
14.	Kandasamy Y, Hartley L, Rudd D, et al. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review[J]. Br J Ophthalmol, 2017, 101(1): 21-24. DOI: 10.1136/bjophthalmol-2016-308828.
15.	王曉艷. 妊娠期高血壓疾病患者的視網膜病變和圍生兒預后的相關性[J]. 當代臨床醫刊, 2022, 35(5): 72-74. DOI: 10.3969/j.issn.2095-9559.2022.05.37.Wang XY. The correlation between retinopathy in patients with hypertensive disorders in pregnancy and perinatal prognosis[J]. The Medical Journal of Thepresent Clinical, 2022, 35(5): 72-74. DOI: 10.3969/j.issn.2095-9559.2022.05.37.
16.	Ge G, Zhang Y, Zhang M. Pregnancy-induced hypertension and retinopathy of prematurity: a meta-analysis[J/OL]. Acta Ophthalmol, 2021, 99(8): e1263-e1273[2021-02-21]. https://pubmed.ncbi.nlm.nih.gov/33611839/. DOI: 10.1111/aos.14827.
17.	Kautzky-Willer A, Winhofer Y, Kiss H, et al. Gestational diabetes mellitus (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 115-128. DOI: 10.1007/s00508-023-02181-9.
18.	Cakir B, Hellstr?m W, Tomita Y, et al. IGF1, serum glucose, and retinopathy of prematurity in extremely preterm infants[J/OL]. JCI Insight, 2020, 5(19): e140363[2020-10-02]. https://pubmed.ncbi.nlm.nih.gov/33004691/. DOI: 10.1172/jci.insight.140363.
19.	Lei C, Duan J, Ge G, et al. Association between neonatal hyperglycemia and retinopathy of prematurity: a meta-analysis[J]. Eur J Pediatr, 2021, 180(12): 3433-3442. DOI: 10.1007/s00431-021-04140-w.
20.	Al-Ofi E, Alrafiah A, Maidi S, et al. Altered expression of angiogenic biomarkers in pregnancy associated with gestational diabetes[J]. Int J Gen Med, 2021, 14: 3367-3375. DOI: 10.2147/ijgm.S316670.
21.	Perais J, Agarwal R, Evans JR, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2023, 2(2): Cd013775[2023-02-22]. https://pubmed.ncbi.nlm.nih.gov/36815723/. DOI: 10.1002/14651858.CD013775.pub2.
22.	Khoshtinat N, Moayeri M, Fakhredin H, et al. Association of hypertensive disorders of pregnancy and gestational diabetes mellitus with developing severe retinopathy of prematurity[J/OL]. Int J Retina Vitreous, 2025, 11(1): 52[2025-04-28]. https://pubmed.ncbi.nlm.nih.gov/40296179/. DOI: 10.1186/s40942-025-00635-y.
23.	Wang F, Hadzic S, Roxlau ET, et al. Retinal tissue develops an inflammatory reaction to tobacco smoke and electronic cigarette vapor in mice[J]. J Mol Med (Berl), 2021, 99(10): 1459-1469. DOI: 10.1007/s00109-021-02108-9.
24.	Hudalla H, Bruckner T, P?schl J, et al. Maternal smoking as an independent risk factor for the development of severe retinopathy of prematurity in very preterm infants[J]. Eye (Lond), 2021, 35(3): 799-804. DOI: 10.1038/s41433-020-0963-4.
25.	Yucel OE, Eraydin B, Niyaz L, et al. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants[J/OL]. BMC Ophthalmol, 2022, 22(1): 367[2022-09-13]. https://pubmed.ncbi.nlm.nih.gov/36096834/. DOI: 10.1186/s12886-022-02591-9.
26.	Zhang H, Jiang Y, Zhang X, et al. Risk factors for retinopathy of prematurity among preterm infants with bronchopulmonary dysplasia[J/OL]. J Matern Fetal Neonatal Med, 2025, 38(1): 2497058[2025-05-13]. https://pubmed.ncbi.nlm.nih.gov/40360447/. DOI: 10.1080/14767058.2025.2497058.
27.	Gantz MG, Carlo WA, Finer NN, et al. Achieved oxygen saturations and retinopathy of prematurity in extreme preterms[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(2): 138-144. DOI: 10.1136/archdischild-2018-316464.
28.	中華醫學會兒科學分會新生兒學組. 早產兒視網膜病預防管理專家共識(2024)[J]. 中華新生兒科雜志, 2024, 39(11): 641-646. DOI: 10.3760/cma.j.issn.2096-2932.2024.11.001.Neonatology Group of Pediatrics Branch, Chinese Medical Association. Expert consensus on the clinical management of retinopathy of prematurity (2024)[J]. Chin J Neonatol, 2024, 39(11): 641-646. DOI: 10.3760/cma.j.issn.2096-2932.2024.11.001.
29.	Grumbine MK, Kamat V, Bao K, et al. Maintaining and assessing various tissue and cell types of the eye using a novel pumpless fluidics system[J/OL]. J Vis Exp, 2023, (197): 10.3791/65399[2023-07-14]. https://pubmed.ncbi.nlm.nih.gov/37522735/. DOI: 10.3791/65399.
30.	王剛, 李乃洋. 綜合性醫院7239例新生兒眼部篩查結果的總結與分析[J]. 國際眼科雜志, 2022, 22(11): 1932-1934. DOI: 10.3980/j.issn.1672-5123.2022.11.34.Wang G, Li NY. Summary and analysis of the results of eye screening in 7239 newborns[J]. Int Eye Sci, 2022, 22(11): 1932-1934. DOI: 10.3980/j.issn.1672-5123.2022.11.34.
31.	吳世元, 陳高艷, 張景怡, 等. 早產兒視網膜病變危險因素分析及氧氣療法應用的再評估[J]. 成都醫學院學報, 2025, 20(1): 54-57. DOI: 10.3969/j.issn.1674-2257.2025.01.012.Wu SY, Chen GY, Zhang JY, et al. Retinopathy of prematurity: a re-exploration of oxygen-related risk factors analysis[J]. Journal of Chengdu Medical College, 2025, 20(1): 54-57. DOI: 10.3969/j.issn.1674-2257.2025.01.012.
32.	Askie LM, Darlow BA, Finer N, et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration[J]. JAMA, 2018, 319(21): 2190-2201. DOI: 10.1001/jama.2018.5725.
33.	Das A, Mhanna M, Sears J, et al. Effect of fluctuation of oxygenation and time spent in the target range on retinopathy of prematurity in extremely low birth weight infants[J]. J Neonatal Perinatal Med, 2018, 11(3): 257-263. DOI: 10.3233/NPM-1757.
34.	Daruich A, Bremond-Gignac D, Behar-Cohen F, et al. Retinopathy of prematurity: from prevention to treatment[J]. Med Sci (Paris), 2020, 36(10): 900-907. DOI: 10.1051/medsci/2020163.
35.	Atakul G, Ceylan G, Sandal O, et al. Closed-loop oxygen usage during invasive mechanical ventilation of pediatric patients (CLOUDIMPP): a randomized controlled cross-over study[J/OL]. Front Med (Lausanne), 2024, 11: 1426969[2024-09-10]. https://pubmed.ncbi.nlm.nih.gov/39318593/. DOI: 10.3389/fmed.2024.1426969.
36.	Roca O, Caritg O, Santafé M, et al. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study)[J/OL]. Crit Care, 2022, 26(1): 108[2022-04-14]. https://pubmed.ncbi.nlm.nih.gov/35422002/. DOI: 10.1186/s13054-022-03970-w.
37.	Almudares F, Gandhi B, Davies J, et al. Oxygen saturation targeting in the neonatal intensive care unit[J/OL]. J Clin Med, 2025, 14(11): 3975[2025-06-04]. https://pubmed.ncbi.nlm.nih.gov/40507737/. DOI: 10.3390/jcm14113975.
38.	海峽兩岸醫藥衛生交流協會新生兒臨床實踐指南專家委員會, 海峽兩岸醫藥衛生交流協會新生兒學專業委員會新生兒循證醫學學組, 《中國當代兒科雜志》編輯部. 早產兒貧血診斷與治療的臨床實踐指南(2025年)[J]. 中國當代兒科雜志, 2025, 27(1): 1-17. DOI: 10.7499/j.issn.1008-8830.2407094.Neonatal Clinical Practice Guidelines Expert Committee of the Cross-Strait Medical and Health Exchange Association, Neonatal Evidence-Based Medicine Group of the Commission of Neonatal Medicine of the Cross-Strait Medical and Health Exchange Association, Editorial Office of the Chinese Journal of Contemporary Pediatrics. Clinical practice guidelines for the diagnosis and treatment of anemia of prematurity(2025)[J]. Chin J Contemp Pediatr, 2025, 27(1): 1-17. DOI: 10.7499/j.issn.1008-8830.2407094.
39.	Fahim NM, Georgieff MK, Zhang L, et al. Endogenous erythropoietin concentrations and association with retinopathy of prematurity and brain injury in preterm infants[J/OL]. PLoS One, 2021, 16(6): e0252655[2021-06-02]. https://pubmed.ncbi.nlm.nih.gov/34077474/. DOI: 10.1371/journal.pone.0252655.
40.	Lundgren P, Hellgren G, Pivodic A, et al. Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity[J]. Pediatr Res, 2019, 86(2): 276-282. DOI: 10.1038/s41390-018-0186-6.
41.	Pai HS, Joy R, Cherian V, et al. Anemia in relation to severity of retinopathy of prematurity in preterm babies born in tertiary care centre in South India[J]. Int J Contemp Pediatr, 2020, 7: 2005-2009. DOI: 10.18203/2349-3291.ijcp20204043.
42.	Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants[J/OL]. Cochrane Database Syst Rev, 2020, 2(2): CD004863[2020-02-11]. https://pubmed.ncbi.nlm.nih.gov/32048730/. DOI: 10.1002/14651858.CD004863.pub6.
43.	Jung N, Kim C, Kim H, et al. Changes to blood-sampling protocol to reduce the sampling amount in neonatal intensive care units: a quality improvement project[J/OL]. J Clin Med, 2023, 12(17): 5712[2023-09-01]. https://pubmed.ncbi.nlm.nih.gov/37685781/. DOI: 10.3390/jcm12175712.
44.	Simon-Szabó Z, Pál S, Pándi A, et al. Retrospective analysis of the prevalence and risk factors of retinopathy of prematurity in a single-center cohort in Romania and comparison with national and European data[J/OL]. Medicina (Kaunas), 2025, 61(1): 149[2025-01-17]. https://pubmed.ncbi.nlm.nih.gov/39859132/. DOI: 10.3390/medicina61010149.
45.	Wang X, Rao R, Li H, et al. Red blood cell transfusion for incidence of retinopathy of prematurity: prospective multicenter cohort study[J/OL]. JMIR Pediatr Parent, 2024, 7: e60330[2024-09-18]. https://pubmed.ncbi.nlm.nih.gov/39297519/. DOI: 10.2196/60330.
46.	Prasad N, Kumar K, Dubey A. Fetal hemoglobin, blood transfusion, and retinopathy of prematurity in preterm infants: an observational, prospective study[J]. Indian J Ophthalmol, 2023, 71(7): 2803-2807. DOI: 10.4103/ijo.Ijo_692_23.
47.	陳冠初, 姚亞鵬, 唐建明, 等. 胎兒血紅蛋白水平與早產兒常見并發癥相關性的研究進展[J]. 中華新生兒科雜志, 2022, 37(4): 377-380. DOI: 10.3760/cma.j.issn.2096-2932.2022.04.024.Chen GC, Yao YP, Tang JM, et al. Research progress on the correlation between fetal hemoglobin level and common complications in premature infants[J]. Chin J Neonatol, 2022, 37(4): 377-380. DOI: 10.3760/cma.j.issn.2096-2932.2022.04.024.
48.	Prasad N, Kumar K, Dubey A. Fetal hemoglobin, blood transfusion, and retinopathy of prematurity in preterm infants: an observational, prospective study[J]. Indian J Ophthalmol, 2023, 71(7): 2803-2807. DOI: 10.4103/ijo.Ijo_692_23.
49.	韓玥, 祝華平. 新生兒臍血輸注的臨床應用進展[J]. 中國當代兒科雜志, 2025, 27(4): 487-492. DOI: 10.7499/j.issn.1008-8830.2409146.Han Y, Zhu HP. Progress in the clinical application of cord blood transfusion in neonates[J]. Chin J Contemp Pediatr, 2025, 27(4): 487-492. DOI: 10.7499/j.issn.1008-8830.2409146.
50.	龔燦, 鄒捷敏, 王桂芳. 早產兒視網膜病變的篩查和危險因素分析[J]. 中國婦幼保健, 2024, 39(9): 1657-1660. DOI: 10.19829/j.zgfybj.issn.1001-4411.2024.09.028.Gong C, Zou JM, Wang GF. Retinopathy of prematurity screening in 360 premature infants[J]. Maternal & Child Health Care of China, 2024, 39(9): 1657-1660. DOI: 10.19829/j.zgfybj.issn.1001-4411.2024.09.028.
51.	Johari M, Karimi A, Mojarad M, et al. Comparative analysis of risk factors for retinopathy of prematurity in single and multiple birth neonates[J/OL]. Int J Retina Vitreous, 2024, 10(1): 21[2024-02-27]. https://pubmed.ncbi.nlm.nih.gov/38414089/. DOI: 10.1186/s40942-024-00536-6.
52.	周蒙, 張雅麗, 楊倩倩, 等. 極低出生體重兒早期營養支持與早產兒視網膜病的相關性研究[J]. 中華新生兒科雜志, 2025, 40(6): 333-338. DOI: 10.3760/cma.j.cn101451-20241203-00413.Zhou M, Zhang YL, Yang QQ, et al. The correlation of early nutritional support and retinopathy of prematurity in very low birth weight infants[J]. Chin J Neonatol, 2025, 40(6): 333-338. DOI: 10.3760/cma.j.cn101451-20241203-00413.
53.	Hellstr?m A, Kermorvant-Duchemin E, Johnson M, et al. Nutritional interventions to prevent retinopathy of prematurity[J]. Pediatr Res, 2024, 96(4): 905-911. DOI: 10.1038/s41390-024-03208-1.
54.	Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants[J/OL]. Cochrane Database Syst Rev, 2020, 3(3): CD007137[2020-04-31]. https://pubmed.ncbi.nlm.nih.gov/32232984/. DOI: 10.1002/14651858.CD007137.pub6.
55.	Ley D, Hallberg B, Hansen-Pupp I, et al. rhIGF-1/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial[J]. J Pediatr, 2019, 206: 56-65. DOI: 10.1016/j.jpeds.2018.10.033.
56.	Fu Z, Nilsson AK, Hellstrom A, et al. Retinopathy of prematurity: metabolic risk factors[J/OL]. Elife, 2022, 11: e80550[2022-11-24]. https://pubmed.ncbi.nlm.nih.gov/36420952/. DOI: 10.7554/eLife.80550.
57.	謝彥茜, 鄭穗聯, 楊暉. 早產兒視網膜病變治療藥物研究進展[J]. 浙江大學學報(醫學版), 2025, 54(3): 411-421. DOI: 10.3724/zdxbyxb-2024-0216.Xie YX, Zheng SL, Yang H. Advances in pharmacological research for retinopathy of prematurity[J]. Journal of Zhejiang University(Medical Sciences), 2025, 54(3): 411-421. DOI: 10.3724/zdxbyxb-2024-0216.
58.	Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin[J]. Am J Clin Nutr, 2015, 101(4): 879-888. DOI: 10.3945/ajcn.114.099291.
59.	Hellstr?m A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial[J]. JAMA Pediatr, 2021, 175(4): 359-367. DOI: 10.1001/jamapediatrics.2020.5653.
60.	Wendel K, Aas MF, Gunnarsdottir G, et al. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants[J]. Clin Nutr, 2023, 42(1): 22-28. DOI: 10.1016/j.clnu.2022.11.012.
61.	Goldstein GP, Leonard SA, Kan P, et al. Prenatal and postnatal inflammation-related risk factors for retinopathy of prematurity[J]. J Perinatol, 2019, 39(7): 964-973. DOI: 10.1038/s41372-019-0357-2.
62.	Villamor-Martinez E, Cavallaro G, Raffaeli G, et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis[J/OL]. PLoS One, 2018, 13(10): e0205838[2018-10-17]. https://pubmed.ncbi.nlm.nih.gov/30332485/. DOI: 10.1371/journal.pone.0205838.
63.	D'Antonio F, Marinceu D, Prasad S, et al. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis[J]. Ultrasound Obstet Gynecol, 2023, 61(4): 436-444. DOI: 10.1002/uog.26136.
64.	Glaser K, H?rtel C, Klingenberg C, et al. Neonatal Sepsis Episodes and Retinopathy of Prematurity in Very Preterm Infants[J/OL]. JAMA Netw Open, 2024, 7(7): e2423933[2024-07-01]. https://pubmed.ncbi.nlm.nih.gov/39052290/. DOI: 10.1001/jamanetworkopen.2024.23933.
65.	Jang JH, Kim JG, Lee YH, et al. The association between amniotic fluid-derived inflammatory mediators and the risk of retinopathy of prematurity[J/OL]. Medicine (Baltimore), 2022, 101(27): e29368[2022-07-08]. https://pubmed.ncbi.nlm.nih.gov/35801764/. DOI: 10.1097/md.0000000000029368.
66.	Sun H, Xia Z, Li M, et al. Identification of genetic factors underlying severe retinopathy of prematurity in preterm infants[J]. Mol Vis, 2025, 31: 33-43.
67.	Choi S, Stein MD, Raifman J, et al. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy[J/OL]. Drug Alcohol Depend, 2021, 229(Pt A): 109162[2021-12-01]. https://pubmed.ncbi.nlm.nih.gov/34768053/. DOI: 10.1016/j.drugalcdep.2021.109162.
68.	Benner M, Lopez-Rincon A, Thijssen S, et al. Antibiotic intervention affects maternal immunity during gestation in mice[J/OL]. Front Immunol, 2021, 12: 685742[2021-08-26]. https://pubmed.ncbi.nlm.nih.gov/34512624/. DOI: 10.3389/fimmu.2021.685742.
69.	Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J/OL]. Ophthalmology, 2021, 128(10): e51-e68[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/34247850/. DOI: 10.1016/j.ophtha.2021.05.031.

1. Crouch ER, Kraker RT, Wallace DK, et al. Secondary 12-month ocular outcomes of a phase 1 dosing study of Bevacizumab for retinopathy of prematurity[J]. JAMA Ophthalmol, 2020, 138(1): 14-20. DOI: 10.1001/jamaophthalmol.2019.4488.
2. Zhang RH, Liu YM, Dong L, et al. Prevalence, years lived with disability, and time trends for 16 causes of blindness and vision impairment: findings highlight retinopathy of prematurity[J/OL]. Front Pediatr, 2022, 10: 735335[2022-03-11]. https://pubmed.ncbi.nlm.nih.gov/35359888/. DOI: 10.3389/fped.2022.735335.
3. Gyllensten H, Humayun J, Sj?bom U, et al. Costs associated with retinopathy of prematurity: a systematic review and meta-analysis[J/OL]. BMJ Open, 2022, 12(11): e057864[2022-11-24]. https://pubmed.ncbi.nlm.nih.gov/36424118/. DOI: 10.1136/bmjopen-2021-057864.
4. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity[J]. Ophthalmology, 2015, 122(1): 200-210. DOI: 10.1016/j.ophtha.2014.07.050.
5. Zhang SM, Fan B, Li YL, et al. Oxidative stress-involved mitophagy of retinal pigment epithelium and retinal degenerative diseases[J]. Cell Mol Neurobiol, 2023, 43(7): 3265-3276. DOI: 10.1007/s10571-023-01383-z.
6. de Almeida VO, Pereira RA, Amantéa SL, et al. Neonatal diseases and oxidative stress in premature infants: an integrative review[J]. J Pediatr (Rio J), 2022, 98(5): 455-462. DOI: 10.1016/j.jped.2021.11.008.
7. Romero-Maldonado S, Montoya-Estrada A, Reyes-Mu?oz E, et al. Efficacy of water-based vitamin E solution versus placebo in the prevention of retinopathy of prematurity in very low birth weight infants: a randomized clinical trial[J/OL]. Medicine (Baltimore), 2021, 100(31): e26765[2021-08-06]. https://pubmed.ncbi.nlm.nih.gov/34397821/. DOI: 10.1097/MD.0000000000026765.
8. Fevereiro-Martins M, Guimar?es H, Marques-Neves C, et al. Retinopathy of prematurity: contribution of inflammatory and genetic factors[J]. Mol Cell Biochem, 2022, 477(6): 1739-1763. DOI: 10.1007/s11010-022-04394-4.
9. Wiszniak S, Schwarz Q. Exploring the intracrine functions of VEGF-A[J/OL]. Biomolecules, 2021, 11(1): 128[2021-01-19]. https://pubmed.ncbi.nlm.nih.gov/33478167/. DOI: 10.3390/biom11010128.
10. Fu Y, Lei C, Qibo R, et al. Insulin-like growth factor-1 and retinopathy of prematurity: a systemic review and meta-analysis[J]. Surv Ophthalmol, 2023, 68(6): 1153-1165. DOI: 10.1016/j.survophthal.2023.06.010.
11. Furuncuoglu U, Vural A, Kural A, et al. Serum vascular endothelial growth factor, insulin-like growth factor-1 and Aflibercept levels in retinopathy of prematurity[J]. Jpn J Ophthalmol, 2022, 66(2): 151-158. DOI: 10.1007/s10384-021-00895-9.
12. 中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專委會. 中國早產兒視網膜病變分類和治療專家共識(2023年)[J]. 中華眼底病雜志, 2023, 39(9): 720-727. DOI: 10.3760/cma.j.cn511434-20230815-00346.Retinal Disease Group of Ophthalmology Branch, Chinese Medical Association, Fundus Disease Specialized Committee of Ophthalmology Branch, Chinese Medical Doctor Association. Expert consensus on the classification and treatment of retinopathy of prematurity in China (2023 edition)[J]. Chin J Ocul Fundus Dis, 2023, 39(9): 720-727. DOI: 10.3760/cma.j.cn511434-20230815-00346.
13. Hunter A, Aitkenhead M, Caldwell C, et al. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy[J]. Hypertension, 2000, 36(6): 965-969. DOI: 10.1161/01.hyp.36.6.965.
14. Kandasamy Y, Hartley L, Rudd D, et al. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review[J]. Br J Ophthalmol, 2017, 101(1): 21-24. DOI: 10.1136/bjophthalmol-2016-308828.
15. 王曉艷. 妊娠期高血壓疾病患者的視網膜病變和圍生兒預后的相關性[J]. 當代臨床醫刊, 2022, 35(5): 72-74. DOI: 10.3969/j.issn.2095-9559.2022.05.37.Wang XY. The correlation between retinopathy in patients with hypertensive disorders in pregnancy and perinatal prognosis[J]. The Medical Journal of Thepresent Clinical, 2022, 35(5): 72-74. DOI: 10.3969/j.issn.2095-9559.2022.05.37.
16. Ge G, Zhang Y, Zhang M. Pregnancy-induced hypertension and retinopathy of prematurity: a meta-analysis[J/OL]. Acta Ophthalmol, 2021, 99(8): e1263-e1273[2021-02-21]. https://pubmed.ncbi.nlm.nih.gov/33611839/. DOI: 10.1111/aos.14827.
17. Kautzky-Willer A, Winhofer Y, Kiss H, et al. Gestational diabetes mellitus (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 115-128. DOI: 10.1007/s00508-023-02181-9.
18. Cakir B, Hellstr?m W, Tomita Y, et al. IGF1, serum glucose, and retinopathy of prematurity in extremely preterm infants[J/OL]. JCI Insight, 2020, 5(19): e140363[2020-10-02]. https://pubmed.ncbi.nlm.nih.gov/33004691/. DOI: 10.1172/jci.insight.140363.
19. Lei C, Duan J, Ge G, et al. Association between neonatal hyperglycemia and retinopathy of prematurity: a meta-analysis[J]. Eur J Pediatr, 2021, 180(12): 3433-3442. DOI: 10.1007/s00431-021-04140-w.
20. Al-Ofi E, Alrafiah A, Maidi S, et al. Altered expression of angiogenic biomarkers in pregnancy associated with gestational diabetes[J]. Int J Gen Med, 2021, 14: 3367-3375. DOI: 10.2147/ijgm.S316670.
21. Perais J, Agarwal R, Evans JR, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2023, 2(2): Cd013775[2023-02-22]. https://pubmed.ncbi.nlm.nih.gov/36815723/. DOI: 10.1002/14651858.CD013775.pub2.
22. Khoshtinat N, Moayeri M, Fakhredin H, et al. Association of hypertensive disorders of pregnancy and gestational diabetes mellitus with developing severe retinopathy of prematurity[J/OL]. Int J Retina Vitreous, 2025, 11(1): 52[2025-04-28]. https://pubmed.ncbi.nlm.nih.gov/40296179/. DOI: 10.1186/s40942-025-00635-y.
23. Wang F, Hadzic S, Roxlau ET, et al. Retinal tissue develops an inflammatory reaction to tobacco smoke and electronic cigarette vapor in mice[J]. J Mol Med (Berl), 2021, 99(10): 1459-1469. DOI: 10.1007/s00109-021-02108-9.
24. Hudalla H, Bruckner T, P?schl J, et al. Maternal smoking as an independent risk factor for the development of severe retinopathy of prematurity in very preterm infants[J]. Eye (Lond), 2021, 35(3): 799-804. DOI: 10.1038/s41433-020-0963-4.
25. Yucel OE, Eraydin B, Niyaz L, et al. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants[J/OL]. BMC Ophthalmol, 2022, 22(1): 367[2022-09-13]. https://pubmed.ncbi.nlm.nih.gov/36096834/. DOI: 10.1186/s12886-022-02591-9.
26. Zhang H, Jiang Y, Zhang X, et al. Risk factors for retinopathy of prematurity among preterm infants with bronchopulmonary dysplasia[J/OL]. J Matern Fetal Neonatal Med, 2025, 38(1): 2497058[2025-05-13]. https://pubmed.ncbi.nlm.nih.gov/40360447/. DOI: 10.1080/14767058.2025.2497058.
27. Gantz MG, Carlo WA, Finer NN, et al. Achieved oxygen saturations and retinopathy of prematurity in extreme preterms[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(2): 138-144. DOI: 10.1136/archdischild-2018-316464.
28. 中華醫學會兒科學分會新生兒學組. 早產兒視網膜病預防管理專家共識(2024)[J]. 中華新生兒科雜志, 2024, 39(11): 641-646. DOI: 10.3760/cma.j.issn.2096-2932.2024.11.001.Neonatology Group of Pediatrics Branch, Chinese Medical Association. Expert consensus on the clinical management of retinopathy of prematurity (2024)[J]. Chin J Neonatol, 2024, 39(11): 641-646. DOI: 10.3760/cma.j.issn.2096-2932.2024.11.001.
29. Grumbine MK, Kamat V, Bao K, et al. Maintaining and assessing various tissue and cell types of the eye using a novel pumpless fluidics system[J/OL]. J Vis Exp, 2023, (197): 10.3791/65399[2023-07-14]. https://pubmed.ncbi.nlm.nih.gov/37522735/. DOI: 10.3791/65399.
30. 王剛, 李乃洋. 綜合性醫院7239例新生兒眼部篩查結果的總結與分析[J]. 國際眼科雜志, 2022, 22(11): 1932-1934. DOI: 10.3980/j.issn.1672-5123.2022.11.34.Wang G, Li NY. Summary and analysis of the results of eye screening in 7239 newborns[J]. Int Eye Sci, 2022, 22(11): 1932-1934. DOI: 10.3980/j.issn.1672-5123.2022.11.34.
31. 吳世元, 陳高艷, 張景怡, 等. 早產兒視網膜病變危險因素分析及氧氣療法應用的再評估[J]. 成都醫學院學報, 2025, 20(1): 54-57. DOI: 10.3969/j.issn.1674-2257.2025.01.012.Wu SY, Chen GY, Zhang JY, et al. Retinopathy of prematurity: a re-exploration of oxygen-related risk factors analysis[J]. Journal of Chengdu Medical College, 2025, 20(1): 54-57. DOI: 10.3969/j.issn.1674-2257.2025.01.012.
32. Askie LM, Darlow BA, Finer N, et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration[J]. JAMA, 2018, 319(21): 2190-2201. DOI: 10.1001/jama.2018.5725.
33. Das A, Mhanna M, Sears J, et al. Effect of fluctuation of oxygenation and time spent in the target range on retinopathy of prematurity in extremely low birth weight infants[J]. J Neonatal Perinatal Med, 2018, 11(3): 257-263. DOI: 10.3233/NPM-1757.
34. Daruich A, Bremond-Gignac D, Behar-Cohen F, et al. Retinopathy of prematurity: from prevention to treatment[J]. Med Sci (Paris), 2020, 36(10): 900-907. DOI: 10.1051/medsci/2020163.
35. Atakul G, Ceylan G, Sandal O, et al. Closed-loop oxygen usage during invasive mechanical ventilation of pediatric patients (CLOUDIMPP): a randomized controlled cross-over study[J/OL]. Front Med (Lausanne), 2024, 11: 1426969[2024-09-10]. https://pubmed.ncbi.nlm.nih.gov/39318593/. DOI: 10.3389/fmed.2024.1426969.
36. Roca O, Caritg O, Santafé M, et al. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study)[J/OL]. Crit Care, 2022, 26(1): 108[2022-04-14]. https://pubmed.ncbi.nlm.nih.gov/35422002/. DOI: 10.1186/s13054-022-03970-w.
37. Almudares F, Gandhi B, Davies J, et al. Oxygen saturation targeting in the neonatal intensive care unit[J/OL]. J Clin Med, 2025, 14(11): 3975[2025-06-04]. https://pubmed.ncbi.nlm.nih.gov/40507737/. DOI: 10.3390/jcm14113975.
38. 海峽兩岸醫藥衛生交流協會新生兒臨床實踐指南專家委員會, 海峽兩岸醫藥衛生交流協會新生兒學專業委員會新生兒循證醫學學組, 《中國當代兒科雜志》編輯部. 早產兒貧血診斷與治療的臨床實踐指南(2025年)[J]. 中國當代兒科雜志, 2025, 27(1): 1-17. DOI: 10.7499/j.issn.1008-8830.2407094.Neonatal Clinical Practice Guidelines Expert Committee of the Cross-Strait Medical and Health Exchange Association, Neonatal Evidence-Based Medicine Group of the Commission of Neonatal Medicine of the Cross-Strait Medical and Health Exchange Association, Editorial Office of the Chinese Journal of Contemporary Pediatrics. Clinical practice guidelines for the diagnosis and treatment of anemia of prematurity(2025)[J]. Chin J Contemp Pediatr, 2025, 27(1): 1-17. DOI: 10.7499/j.issn.1008-8830.2407094.
39. Fahim NM, Georgieff MK, Zhang L, et al. Endogenous erythropoietin concentrations and association with retinopathy of prematurity and brain injury in preterm infants[J/OL]. PLoS One, 2021, 16(6): e0252655[2021-06-02]. https://pubmed.ncbi.nlm.nih.gov/34077474/. DOI: 10.1371/journal.pone.0252655.
40. Lundgren P, Hellgren G, Pivodic A, et al. Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity[J]. Pediatr Res, 2019, 86(2): 276-282. DOI: 10.1038/s41390-018-0186-6.
41. Pai HS, Joy R, Cherian V, et al. Anemia in relation to severity of retinopathy of prematurity in preterm babies born in tertiary care centre in South India[J]. Int J Contemp Pediatr, 2020, 7: 2005-2009. DOI: 10.18203/2349-3291.ijcp20204043.
42. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants[J/OL]. Cochrane Database Syst Rev, 2020, 2(2): CD004863[2020-02-11]. https://pubmed.ncbi.nlm.nih.gov/32048730/. DOI: 10.1002/14651858.CD004863.pub6.
43. Jung N, Kim C, Kim H, et al. Changes to blood-sampling protocol to reduce the sampling amount in neonatal intensive care units: a quality improvement project[J/OL]. J Clin Med, 2023, 12(17): 5712[2023-09-01]. https://pubmed.ncbi.nlm.nih.gov/37685781/. DOI: 10.3390/jcm12175712.
44. Simon-Szabó Z, Pál S, Pándi A, et al. Retrospective analysis of the prevalence and risk factors of retinopathy of prematurity in a single-center cohort in Romania and comparison with national and European data[J/OL]. Medicina (Kaunas), 2025, 61(1): 149[2025-01-17]. https://pubmed.ncbi.nlm.nih.gov/39859132/. DOI: 10.3390/medicina61010149.
45. Wang X, Rao R, Li H, et al. Red blood cell transfusion for incidence of retinopathy of prematurity: prospective multicenter cohort study[J/OL]. JMIR Pediatr Parent, 2024, 7: e60330[2024-09-18]. https://pubmed.ncbi.nlm.nih.gov/39297519/. DOI: 10.2196/60330.
46. Prasad N, Kumar K, Dubey A. Fetal hemoglobin, blood transfusion, and retinopathy of prematurity in preterm infants: an observational, prospective study[J]. Indian J Ophthalmol, 2023, 71(7): 2803-2807. DOI: 10.4103/ijo.Ijo_692_23.
47. 陳冠初, 姚亞鵬, 唐建明, 等. 胎兒血紅蛋白水平與早產兒常見并發癥相關性的研究進展[J]. 中華新生兒科雜志, 2022, 37(4): 377-380. DOI: 10.3760/cma.j.issn.2096-2932.2022.04.024.Chen GC, Yao YP, Tang JM, et al. Research progress on the correlation between fetal hemoglobin level and common complications in premature infants[J]. Chin J Neonatol, 2022, 37(4): 377-380. DOI: 10.3760/cma.j.issn.2096-2932.2022.04.024.
48. Prasad N, Kumar K, Dubey A. Fetal hemoglobin, blood transfusion, and retinopathy of prematurity in preterm infants: an observational, prospective study[J]. Indian J Ophthalmol, 2023, 71(7): 2803-2807. DOI: 10.4103/ijo.Ijo_692_23.
49. 韓玥, 祝華平. 新生兒臍血輸注的臨床應用進展[J]. 中國當代兒科雜志, 2025, 27(4): 487-492. DOI: 10.7499/j.issn.1008-8830.2409146.Han Y, Zhu HP. Progress in the clinical application of cord blood transfusion in neonates[J]. Chin J Contemp Pediatr, 2025, 27(4): 487-492. DOI: 10.7499/j.issn.1008-8830.2409146.
50. 龔燦, 鄒捷敏, 王桂芳. 早產兒視網膜病變的篩查和危險因素分析[J]. 中國婦幼保健, 2024, 39(9): 1657-1660. DOI: 10.19829/j.zgfybj.issn.1001-4411.2024.09.028.Gong C, Zou JM, Wang GF. Retinopathy of prematurity screening in 360 premature infants[J]. Maternal & Child Health Care of China, 2024, 39(9): 1657-1660. DOI: 10.19829/j.zgfybj.issn.1001-4411.2024.09.028.
51. Johari M, Karimi A, Mojarad M, et al. Comparative analysis of risk factors for retinopathy of prematurity in single and multiple birth neonates[J/OL]. Int J Retina Vitreous, 2024, 10(1): 21[2024-02-27]. https://pubmed.ncbi.nlm.nih.gov/38414089/. DOI: 10.1186/s40942-024-00536-6.
52. 周蒙, 張雅麗, 楊倩倩, 等. 極低出生體重兒早期營養支持與早產兒視網膜病的相關性研究[J]. 中華新生兒科雜志, 2025, 40(6): 333-338. DOI: 10.3760/cma.j.cn101451-20241203-00413.Zhou M, Zhang YL, Yang QQ, et al. The correlation of early nutritional support and retinopathy of prematurity in very low birth weight infants[J]. Chin J Neonatol, 2025, 40(6): 333-338. DOI: 10.3760/cma.j.cn101451-20241203-00413.
53. Hellstr?m A, Kermorvant-Duchemin E, Johnson M, et al. Nutritional interventions to prevent retinopathy of prematurity[J]. Pediatr Res, 2024, 96(4): 905-911. DOI: 10.1038/s41390-024-03208-1.
54. Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants[J/OL]. Cochrane Database Syst Rev, 2020, 3(3): CD007137[2020-04-31]. https://pubmed.ncbi.nlm.nih.gov/32232984/. DOI: 10.1002/14651858.CD007137.pub6.
55. Ley D, Hallberg B, Hansen-Pupp I, et al. rhIGF-1/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial[J]. J Pediatr, 2019, 206: 56-65. DOI: 10.1016/j.jpeds.2018.10.033.
56. Fu Z, Nilsson AK, Hellstrom A, et al. Retinopathy of prematurity: metabolic risk factors[J/OL]. Elife, 2022, 11: e80550[2022-11-24]. https://pubmed.ncbi.nlm.nih.gov/36420952/. DOI: 10.7554/eLife.80550.
57. 謝彥茜, 鄭穗聯, 楊暉. 早產兒視網膜病變治療藥物研究進展[J]. 浙江大學學報(醫學版), 2025, 54(3): 411-421. DOI: 10.3724/zdxbyxb-2024-0216.Xie YX, Zheng SL, Yang H. Advances in pharmacological research for retinopathy of prematurity[J]. Journal of Zhejiang University(Medical Sciences), 2025, 54(3): 411-421. DOI: 10.3724/zdxbyxb-2024-0216.
58. Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin[J]. Am J Clin Nutr, 2015, 101(4): 879-888. DOI: 10.3945/ajcn.114.099291.
59. Hellstr?m A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial[J]. JAMA Pediatr, 2021, 175(4): 359-367. DOI: 10.1001/jamapediatrics.2020.5653.
60. Wendel K, Aas MF, Gunnarsdottir G, et al. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants[J]. Clin Nutr, 2023, 42(1): 22-28. DOI: 10.1016/j.clnu.2022.11.012.
61. Goldstein GP, Leonard SA, Kan P, et al. Prenatal and postnatal inflammation-related risk factors for retinopathy of prematurity[J]. J Perinatol, 2019, 39(7): 964-973. DOI: 10.1038/s41372-019-0357-2.
62. Villamor-Martinez E, Cavallaro G, Raffaeli G, et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis[J/OL]. PLoS One, 2018, 13(10): e0205838[2018-10-17]. https://pubmed.ncbi.nlm.nih.gov/30332485/. DOI: 10.1371/journal.pone.0205838.
63. D'Antonio F, Marinceu D, Prasad S, et al. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis[J]. Ultrasound Obstet Gynecol, 2023, 61(4): 436-444. DOI: 10.1002/uog.26136.
64. Glaser K, H?rtel C, Klingenberg C, et al. Neonatal Sepsis Episodes and Retinopathy of Prematurity in Very Preterm Infants[J/OL]. JAMA Netw Open, 2024, 7(7): e2423933[2024-07-01]. https://pubmed.ncbi.nlm.nih.gov/39052290/. DOI: 10.1001/jamanetworkopen.2024.23933.
65. Jang JH, Kim JG, Lee YH, et al. The association between amniotic fluid-derived inflammatory mediators and the risk of retinopathy of prematurity[J/OL]. Medicine (Baltimore), 2022, 101(27): e29368[2022-07-08]. https://pubmed.ncbi.nlm.nih.gov/35801764/. DOI: 10.1097/md.0000000000029368.
66. Sun H, Xia Z, Li M, et al. Identification of genetic factors underlying severe retinopathy of prematurity in preterm infants[J]. Mol Vis, 2025, 31: 33-43.
67. Choi S, Stein MD, Raifman J, et al. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy[J/OL]. Drug Alcohol Depend, 2021, 229(Pt A): 109162[2021-12-01]. https://pubmed.ncbi.nlm.nih.gov/34768053/. DOI: 10.1016/j.drugalcdep.2021.109162.
68. Benner M, Lopez-Rincon A, Thijssen S, et al. Antibiotic intervention affects maternal immunity during gestation in mice[J/OL]. Front Immunol, 2021, 12: 685742[2021-08-26]. https://pubmed.ncbi.nlm.nih.gov/34512624/. DOI: 10.3389/fimmu.2021.685742.
69. Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J/OL]. Ophthalmology, 2021, 128(10): e51-e68[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/34247850/. DOI: 10.1016/j.ophtha.2021.05.031.

Chinese Journal of Ocular Fundus Diseases

Latest ArticlesResearch progress on risk factors for retinopathy of prematurity

Abstract Full text Figures/Tables Video References Cited by

Format

Content